Celyad Oncology SA (CYAD) Issues Q4 Business Update and 2023 Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/3/2026
- Wall St indexes climb after Fed's Waller says he could support rate hold
- Fed’s Waller open to September rate hold - if disinflation holds up
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Nvidia to acquire AI platform Hugging Face in landmark $12.9B deal
- Tesla to unveil Cybercab Texas today, details are few
Celyad Oncology provides fourth quarter 2022 business update and 2023 outlook
February 3, 2023 1:00 AM ESTCelyad Oncology has implemented a strategic shift from an organization focused on clinical development to one fully harnessing the true potential of its proprietary technology platforms and intellectual property
The company is now prioritizing internal discovery endeavors to tackle the major current limitations of CAR T-cell therapiesAs of December 31, 2022, the Company ended the year with an unaudited treasury position of 12.4 million ($13.3 million)MONT-SAINT-GUIBERT, Belgium, Feb. 03, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext & Nasdaq: CYAD) (the Company), a biotechnology company focused on... More
